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Do single-arm trials have a role in drug
development plans incorporating
randomised trials?
Michael J. Grayling* and Adrian P. Mander
Often, single-arm trials are used in phase II to gather the first evidence of an oncological drug’s efficacy, with drug activity
determined through tumour response using the RECIST criterion. Provided the null hypothesis of ‘insufficient drug activity’ is
rejected, the next step could be a randomised two-arm trial. However, single-arm trials may provide a biased treatment effect
because of patient selection, and thus, this development planmay not be an efficient use of resources. Therefore, we compare
the performance of development plans consisting of single-arm trials followedby randomised two-arm trialswith stand-alone
single-stage or group sequential randomised two-arm trials. Through this, we are able to investigate the utility of single-arm
trials and determine the most efficient drug development plans, setting our work in the context of a published single-arm
non-small-cell lung cancer trial. Reference priors, reflecting the opinions of ‘sceptical’ and ‘enthusiastic’ investigators, are
used to quantify and guide the suitability of single-arm trials in this setting. We observe that the explored development plans
incorporating single-arm trials are often non-optimal. Moreover, even the most pessimistic reference priors have a
considerable probability in favour of alternative plans. Analysis suggests expected sample size savings of up to 25% could
havebeenmade, and the issues associatedwith single-arm trials avoided, for thenon-small-cell lung cancer treatment through
direct progression to a group sequential randomised two-arm trial. Careful consideration should thus be given to the use
of single-arm trials in oncological drug development when a randomised trial will follow. Copyright © 2015 The Authors.
Pharmaceutical Statistics published by JohnWiley & Sons Ltd.
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1. INTRODUCTION
The development of a drug carries significant cost in terms of time
[1] and money [2]. Consequently, research into efficient designs
for clinical trials is extremely active. Here, we focus on improving
efficiency in phase II oncology trials. Because these early phase
trials do not aim to provide definitive evidence of drug efficacy,
much greater flexibility occurs in their design [3], and a healthy
debate exists in terms of which is the best [4–13].
Ultimately, these trials aim to make a go/no-go decision and
have classically taken the form of single-arm trials [11,14], with
the most commonly used design being Simon’s two-stage [15].
Indeed, a recent review indicated that over 20%of all phase II trials
were Simon’s designs [16]. Single-arm trials have been favoured
because of their low expected sample size and ability to stop tri-
als quickly when a drug has low activity. However, they do not
have a causal interpretation because of a lack of randomisation.
This means, trialists can introduce a selection bias leading to a
biased treatment effect and a lack of confidence in a positive
result. Subsequently, significant attention has been given lately to
approaches for randomised phase II development plans [13].
However, randomised trials frequently require large sample
sizes, and so the debate over their usage in phase II has contin-
ued. Oneway to potentially handle the issue of larger sample sizes
though is to use a group sequential trial [17]. These designs intro-
duce a fixed number of interim analyses into a randomised trial,
allowing early stopping for go or no-go decisions, lowering the
risk of exposure to inferior treatments.
With the debate over the optimal phase II development plan
on-going, a number of recent studies have compared the perfor-
mance of single-arm and randomised two-arm trials under the
influence of several factors [18–21]. It has been suggested that
when possible randomised two-arm trials should be used, even
at the cost of higher sample sizes [19]. Moreover, work has been
conducted to explore which may be the best design for pre-
dicting phase III success [22,23], also concluding it may often be
preferable to use randomised two-arm trials in phase II.
With the cost of late phase trials ever increasing, it could be
argued that single-arm trials alone should not be used as evi-
dence for progression to phase III. Therefore, if a randomised trial
is to be employed before a large-scale confirmatory trial, we can
question the role single-arm trials have to play in the future. It
may be more efficient to proceed directly to a randomised trial
at phase II. Thus, in this work, we assess the benefits in terms of
efficiency of a single-arm followed by two-arm trial development
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plan, in comparison to a sole two-arm trial development plan.
Reference priors [24] reflecting the opinions of ‘sceptical’ and
‘enthusiastic’ clinicians are used to quantify the probability that
one of the development plans incorporating a single-arm trial
should be utilised. We set our analysis in the context of a com-
pleted trial on bavituximab plus paclitaxel and carboplatin for the
treatment of advanced non-small-cell lung cancer [25].
2. MATERIALS ANDMETHODS
2.1. Drug development scenario
We assume at the initiation of phase II that the maximum tol-
erated dose for an experimental treatment, or treatment combi-
nation, has been determined, and we are interested in initiating
trials seeking to detect an efficacy signal. Specifically, we wish
to compare this experimental intervention with the current stan-
dard (control) treatment, and determine if there is substantial
activity against tumours to warrant further exploration. Addition-
ally, we assume that the number of potential patients available for
inclusion in the trial will not limit our design choices. Our ultimate
goal is then to specify either a go decision of recommending fur-
ther exploration, or a no-go decision of recommending no further
exploration of the experimental treatment. To this end, we con-
sider six possible development plans, consisting of randomised
two-arm trials, with or without a preceding single-arm stage.
We assume a binary endpoint, because in this setting patient
response, evaluated using the RECIST criterion [26], is usually the
primary endpoint of interest. The work presented here could be
extended to consider alternative endpoints, such as progression
free survival, or to consider alternative development plans, but is
not the focus of this paper. Moreover, we do not deal here with
the case of rare diseases, for which there are few available partici-
pants, or the case when there is no presently available treatment.
In these instances, alternate methods would be appropriate.
The hypotheses tested for the true response rate in the experi-
mental treatment arm, pE , by the single-arm trials are:
Hs0 : pE 6 p0,
Hs1 : pE > p1 > p0.
Here, p0 represents the fixed null response probability at which
the drug will be considered to have insubstantial activity to be
of further interest and can be chosen based on the historical
response rate of the control treatment. Additionally, p1 represents
the minimum desired response for the experimental treatment
to constitute a clinically relevant benefit, worthy of further explo-
ration. The type-I error is controlled at pE D p0 to a level ˛s, and
type-II error at pE D p1 to ˇs.
The randomised two-arm trials test the following hypotheses
for the difference in the true response rate of the experimental
and control treatment arms, pD D pE  pC :
HR0 : pD 6 0,
HR1 : pD > p1  p0.
Here, type-I error is controlled at pD D 0 to a level ˛R , and
type-II error at pD D p1  p0 to a level ˇR.
In this work, the following six development plans are
compared:
 DP1: A Simon’s two-stage HS0 -optimal single-arm trial
[15,27], followed by a randomised two-arm trial if the null
hypothesis of the single-arm stage, HS0 is rejected.
 DP2: A Simon’s two-stage HS0 -optimal single-arm trial with
early stopping for efficacy [27], followed by a randomised
two-arm trial if the null hypothesis of the single-arm stage,
HS0, is rejected. DP3: A single-stage randomised two-arm trial.
 DP4: A group sequential two-arm trial, with 3 stages, and
early go/no-go stopping according to error spendingmeth-
ods [28] with the ‘rho-family’ spending function [17].
 DP5: A group sequential two-arm trial with interim analy-
ses for no-go decisions timed according to the sample sizes
of each stage of the identified Simon’s two-stage design in
DP1, followed by an additional final analysis for go/no-go
decisions timed to provide the correct power. Stopping
boundaries and sample sizes are identified through error
spendingmethods [28]with the ‘rho-family’ spending func-
tion [17].
 DP6: A group sequential two-arm trial with an interim
analysis for a no-go decision timed according to the total
sample size of the identified Simon’s two-stage design
in DP1, followed by two additional equally spaced anal-
yses for go/no-go decisions timed to provide the correct
power. Stopping boundaries and sample sizes are identified
through error spending methods [28] with the ‘rho-family’
spending function [17].
These six development plans thus allow us to consider the
most likely single-arm, followed by randomised two-arm designs,
along with standard single-stage and group sequential two-arm
designs, and finally, two group sequential designs that are com-
parable with the single-arm incorporating plans in terms of their
timed interim analyses. Therefore, they provide coverage of a
wide array of possible designs for investigators.
For DP1–DP2, we declare a final go decision for the experimen-
tal treatment if bothHS0 andH
R
0 are rejected,whereas for DP3–DP6,
a go decision occurs when only HR0 is rejected (because H
S
0 is not
tested for DP3–DP6). All development plans are designed to have
equal development plan wide type-I and type-II error rates, ˛ and
ˇ, under the ‘global null hypothesis’ .H0/ pC D pE D p0 and
‘global alternative hypothesis’ .H1/ pC D p0, pE D p1, respec-
tively. This allows their efficiencies to be compared whilst con-
trolling the operating characteristics to be equal. Specifically, to
ensure the type-I and type-II error rates of DP1–DP2 are ˛ and ˇ
across their possible two trials, we set the single-arm and two-arm
stages to each have type-I error rate ˛S D ˛R D p˛ and type-II
error rate ˇSDˇRD1
p
1ˇ. A pictorial description of the plans
can be found in Supplementary Figure 1. Note that we do not
consider optimal spending of the type-I and type-II errors
between the two studies in DP1–DP2. Furthermore, this formula-
tion ensures the type-I error rate of DP3–DP6 is always less than or
equal to ˛ (strong control) in the region pE 6 pC . However, there
will be instances when pE 6 pC and DP1–DP2 have a type-I error
rate greater than ˛. If strong control is desired for these devel-
opment plans ˛R could be set to ˛. Finally, we will refer to the
case pC D 0.15, pE D 0.41 as the ‘observed response rates’ .O/
(see below).
2.2. Design performance
With the aforementioned specification, to determine designs for
each of the development plans, we need only to specify p0,
p1, ˛ and ˇ. Given values for these, the HS0 -optimal Simon’s
two-stage designs were found using an exhaustive search
over rejection/acceptance boundaries and sample sizes. For the14
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Figure 1. Developmentplan performances for p0 D 0.15, p1 D 0.3,˛ D 0.0025,ˇ D 0.36. The expected sample size;E.NjpC , pE/, powerl; P.pC , pE/, and ‘power per patient’;
P.pC , pE/=E.NjpC , pE/, of the six development plans, across the complete possible range of true response rates in the control .pC/ and treatment .pE/ arms is depicted. The
dotted white line in the P.pC , pE/ plots indicates the contour P.pC , pE/ D ˛.
single-stage randomised two-arm design, the minimum sample
size required was calculated using the normal approximation to
the difference of two binomial proportions [29]. Finally, as noted
in the preceding sections, the group sequential designs were
identified using the error spending method of Lan and DeMets
[28], using the ‘rho-family’ spending function [17] with spend-
ing parameter 1. Further information on how these designs were
determined can be found in the Supplementary Materials.
Following the development plan specifications, for each pair of
possible true response rates in the control and experimental treat-
ment arms, .pC , pE/–Œ0, 1  Œ0, 1, the probability that a go deci-
sion would be declared for each development plan (the power),
P.pC , pE/ D P.RejectH0jpC , pE/, and the associated expected
sample size, E.NjpC , pE/, was then determined. Full descriptions
of the formulae used to compute P.pC , pE/ and E.NjpC , pE/ are
also provided in the Supplementary Materials. Note that we here
simply compute the probability of rejecting H0, we do not make a
distinction as to whether this was the correct decision.
2.3. Software
All analyses were performed using the software environment R
[30]. All code is available upon request from the authors.
2.4. Optimality criteria
In order to determine the optimal development plan, of the six
considered, for each pair of true response rates, .pC , pE/, several
criteria were used. Classically, trial designs have been considered
optimal subject to having the smallest expected sample at some
minimum level of power. More recently however, the concept of
‘power per patient’ has been proposed as a possible new optimal-
ity criteria for clinical trial designs [31]; allowing the two important
factors of power and expected sample size to be combined into
a single metric and designs with similar expected sample size but
differing power to be compared more easily. Thus, the following
four criteria were used here to determine the optimal design for
each pair of values .pC , pE/:
 OC1: minfE.NjpC , pE/g,
 OC2: IfP.pC ,pE/>1ˇg minfE.NjpC , pE/g,
 OC3: maxfP.pC , pE/=E.NjpC , pE/g,
 OC4: IfP.pC ,pE/>1ˇg maxfP.pC , pE/=E.NjpC , pE/g.
where I is the indicator function, which is 1 when there is at
least 100.1  ˇ/% power and 0 otherwise. OC1 and OC3 allowed
optimal development plans to be determined in zones of the
parameter space where no plan met the minimal power criteria.
Thus, OC1 simply declares the trial with the smallest expected
sample size as optimal, whilst OC2 seeks the trial with the min-
imal expected sample size subject to having power of at least
100.1  ˇ/%. Further, OC3 searches for the maximal power per
patient, with OC4 desiring maximal power per patient subject to
having power of at least 100.1  ˇ/%.
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2.5. Reference priors
Now, in order to determine the appropriate usage of single-arm
studies to a researcher, we compute probabilities that each of the
six development plans is optimal after placing priors on the value
of pE with pC D p0. Explicitly, for each optimality criteria in turn,
the prior probability of configurations .pE , pC D p0/ for which
each development plan is known to be optimal is taken to be
the probability that this development plan should be employed.
Specifically, we utilise sceptic and enthusiast beta distribution ref-
erence priors [24], to reflect believed distributions of likely values
for pE . A sceptic was assumed to believe the distribution should
be centred on p0, with only a 10% chance that pE > p1. Whilst
an enthusiast would believe the distribution should be centred
on p1, with only a 10% chance that pE < p0. Full details on
how the beta distributions were determined are provided in the
Supplementary Materials. Once the reference priors have been
utilised to determine the probability each of the development
plans should be used, the appropriate usage of the single-arm
incorporating development plans versus the randomised
two-arm only plans, according to each optimality criteria, can
be quantified.
Note that the above-mentioned does not involve any Bayesian
analysis. Moreover, note that the distributions here are simply
two chosen to represent possible (extreme) views of researchers.
Much research exists on eliciting prior opinion, and a prior could
be constructed to reflect the opinion of any researcher [32]. More-
over, we have assumed here that historical data would allow the
value of the control treatment to be known relatively accurately
and have thus set pC D p0 when working with the reference pri-
ors. However, you need not make this assumption, if, for example,
changes in supportive care indicate that the control treatment
response rate may have changed.
2.6. Non-small-cell lung cancer trial analysis
A single-arm study was recently completed to explore whether
bavituximab in combination with paclitaxel and carboplatin
could be a useful treatment regimen for advanced non-small-cell
lung cancer [25]. The trial had a type-I error rate of 5%, and a
type-II error rate of 20%, for p0 D 0.15 and p1 D 0.3, employing a
(non-optimal) Simon’s two-stage design. Forty-nine patients were
recruited, and an objective response rate of 41% was observed,
based on one complete response and 19 partial responses.
Consequently, the null-hypothesis of the trial was rejected, and a
randomised trial of this regimen has now begun, comparing the
performance of bavituximab with paclitaxel and carboplatin, to
paclitaxel and carboplatin alone.
Taking p0 D 0.15, p1 D 0.3, with ˛ D 0.0025 and ˇ D 0.36
(such that ˛S D 0.05 and ˇS D 0.2 for DP1–DP2, as in the com-
pleted trial), we explore the efficiency of our six development
plans in the context of determining the efficacy of bavituximab
with paclitaxel and carboplatin. Moreover, a recently completed
phase III trial estimated the response rate of paclitaxel and carbo-
platin alone for non-small-cell lung cancer to be 15% [33]. Thus,
we are able to confidentlymake the assumption that pC D p0 and
quantify how likely as a sceptic or enthusiast you should utilise
a single-arm trial for this experimental treatment. Recommenda-
tions on how appropriate the investigators use of a single-arm
trial was can then be made.
3. RESULTS
3.1. Development plan specifications
The design of each development plan was determined for ˛ D
0.0025, ˇ D 0.36, p0 D 0.15 and p1 D 0.3 and is presented
in Table I. The Simon’s two-stage designs, with and without early
efficacy stopping, both required a maximum sample size of 55
patients and a first stage sample size of 19 patients. These designs
would potentially, for DP1–DP2, be followed by a single-stage ran-
domised two-arm trial of 186 patients. DP3, the sole single-stage
randomised two-arm trial, required 302 patients. DP4 required
120 patients for each stage, whilst DP5 as stated earlier, times
interim analyses for futility after 20 and 56 patients to correspond
with the identified Simon’s two-stage design, with a final analy-
sis after 310 patients. Finally, DP6 required slightly more patients,
timing analyses after 56, 202 and 346 patients. All six devel-
opment plans can be observed to have the desired operating
characteristics under H0 and H1.
3.2. Development plan performance
Figure 1 shows the expected sample size, power and power per
patient of each of the development plans across all possible
Table I. Development plan specifications and operating characteristics.
Randomised two-arm
Simon’s two- sample Size
stage design n1 n2 n3 max N E.NjH0/ P.H0/ E.NjH1/ P.H1/ E.NjO/ P.O/
DP1 3/19 12/55 186 N/A N/A 241 39.2 0.0024 199.1 0.6413 236.6 0.9735
DP2 (3 7)/19 12/55 186 N/A N/A 241 39.3 0.0024 192.7 0.6419 216.9 0.9736
DP3 N/A 302 N/A N/A 302 302.0 0.0025 302.0 0.6427 302.0 0.9929
DP4 N/A 120 240 360 360 146.7 0.0025 252.7 0.6479 176.7 0.9899
DP5 N/A 20 56 310 310 199.8 0.0025 292.6 0.6417 307.1 0.9844
DP6 N/A 56 202 346 346 146.6 0.0025 256.8 0.6424 213.2 0.9872
The identified designs for each of the four development plans are displayed. In addition, the probability of determining
a go decision under H0; when pC D pE D p0, and under H1; pC D pE D p1 is displayed, along with the expected sample
sizes in these scenarios and for the observed response rates in the conducted trial, O; pC D 0.15, pE D 0.41. Expected
sample sizes are given to 1 decimal place, and powers to 4 decimal places.14
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values of true response rates in the control and treatment
arms. Small expected sample sizes for the development plans
incorporating a single-arm trial (DP1–DP2) exist for low lev-
els of pE . This would be expected given the drug would be
unlikely to reach the randomised stage. Additionally, a slightly
lower expected sample size can be seen when early go stop-
ping is incorporated into the Simon’s two-stage design (DP2),
than over its exclusion (DP1), as would be anticipated. Expected
sample sizes drop substantially for pE  pC , or pE  pC ,
in the group sequential design DP4, as the trial would likely
stop early. Similarly, sample sizes drop for DP5–DP6 when pE 
pC due to the presence of early no-go stopping throughout,
whilst they have larger expected samples when pE  pC
owing to the fact that early go stopping is only present at latter
interim analyses.
Power can be seen to be comparable across all development
plans with the only noticeable differences around the region
where pC Ð pE , and for small pC and pE in the single-arm
incorporating plans (DP1–DP2).
Finally, notable differences canbe seen in the power per patient
possessed by each development plan. Whilst all six development
plans have low values when pE  pC , as would be expected, DP4
has substantially higher values for pE  pC .
3.3. Optimal development plans
Utilising the computed development plan performances, and our
four optimality criteria, the optimal development plans for each
pair of values .pC , pE/–Œ0, 1  Œ0, 1 were determined and are dis-
played in Figure 2. Summary information for H0, H1 and O is also
provided in Table I.
For the global null hypothesis H0, DP1 is found to be opti-
mal under OC1 and DP2 optimal under OC3. In particular, the
expected sample sizes of DP1–DP2 are substantially smaller here
(39.2 and 39.3, respectively) in comparison to DP3–DP6 (302.0,
146.7, 199.8 and 146.6, respectively).
For the global alternative hypothesis H1, DP2 is optimal under
all four optimality criteria. Here though, the sample sizes aremore
comparable (for example, 192.7 for DP2 in comparison with 252.7
for DP4). Moreover, for the observed response rates O, DP4 was
optimal under all four optimality criteria, with an expected sam-
ple size of 176.7 in comparisonwith the next best performingDP6
with an expected sample size of 213.2.
Looking across the full parameter space Œ0, 1  Œ0, 1, and the
optimality criteria, we observe very few areas in which DP1 is
optimal. Indeed, it only performs best for OC1 when pE is small.
Moreover, we observe no instance in which DP3 is optimal. For
OC1, we observe large portions of the region pE 6 pC in which
Figure 2. Optimal development plans. For the four optimality criteria (OC1–OC4), the optimal development plan is provided at each point in the parameter space
Œ0, 1  Œ0, 1.
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DP5 and DP6 are optimal. For OC2 and OC4, where minimal
power constraints are enforced, large regions where no develop-
ment plan meets the requirements can be observed. In general,
when an optimal development plan exists, it is either DP2 or DP4,
and we observe many areas of the parameter space in which
single-arm incorporating plans are not optimal. Specifically, DP4
is optimal in the regions where pE  pC , whilst DP2 performs
better under OC3 for pE  pC .
3.4. Sceptic and enthusiast development plan distributions
Figure 3 depicts the reference priors and the associated regions
of values for pE in which a sceptic or enthusiast should utilise
each development plan, along with the performance of each
development plan, for each optimality criteria. From these distri-
butions, the probabilities of using a single-arm trial (i.e. DP1–DP2),
not using a single-arm trial (i.e. DP3–DP6), and there being no
optimal development plan, according to each optimality criteria,
were computed and are shown in Table II.
It is clear that as pE increases, for all four optimality criteria, DP4
becomes the clear optimal design. However, for smaller values
of pE , the performance between the development plans is more
comparable.
We see that seeking to minimise the expected sample size
(OC1), the usage of a single-arm trial can be seen to outperform
the two-arm only development plans as a sceptic or an enthusi-
ast (0.967 and 0.557 to 0.033 and 0.443, respectively), although
the appropriate use probabilities are substantially closer as an
enthusiast. In contrast, when power constraints are added to this
criterion (OC2), the two-arm only development plans are far more
likely to be optimal as an enthusiast (0.443 to 0.147), but slightly
less likely as a sceptic (0.033 to 0.068).
Similar patterns are observed for the criteria based on
power per patient (OC3–OC4), where for OC3 the single-arm
Figure 3. ‘Sceptic’ and ‘Enthusiast’ development plan distributions. Beta distributions depict the optimal development plans according to the optimality criteria (OC1–OC4),
and being either a ‘sceptic’ or an ‘enthusiast’. Additionally, the performance of each development plan for each optimality criteria, across values of pE , is displayed.14
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Table II. ‘Sceptic’ and ‘enthusiast’ probabilities of utilising a single-arm trial.
Sceptic Enthusiast
P.C/ P.S/ P.T/ P.C/ P.S/ P.T/
OC1: minfE.N/g 0.000 0.967 0.033 0.000 0.557 0.443
OC2: IfP>1ˇgminfE.N/g 0.898 0.068 0.033 0.410 0.147 0.443
OC3: maxfP=E.N/g 0.000 0.798 0.202 0.000 0.502 0.498
OC4: IfP>1ˇgmaxfP=E.N/g 0.898 0.064 0.038 0.410 0.131 0.458
The probability of there being no optimal development plan under each
optimality criteria .C/, of a single-arm trial utilising development plan being
optimal .S/, and of a non-single-arm trial utilising development plan being
optimal .T/ is shown for each optimality criteria, and according to being either
a sceptic or enthusiast. All probabilities are given to 3 decimal places.
incorporating plans are preferred as either a sceptic or an enthu-
siast, whilst for OC4, the two-arm only plans are greatly favoured
as an enthusiast but are less likely to be optimal as a sceptic.
4. DISCUSSION
Future progress in cancer therapy can be accelerated by using
better drug development plans in phase II. In this area a
long-standing debate exists over the use of single-arm trials.
Recent work has suggested that when the available patient popu-
lation allows so, a randomised two-arm trial may be preferable to
a single-arm trial [19]. But, proponents of single-arm designs may
continue to favour their use; employing themprior to randomised
trials, and citing their ability to identify poorly performing exper-
imental treatments at low sample size. However, this may be less
efficient than proceeding directly to a randomised two-arm trial.
We therefore considered whether a randomised two-arm trial
alone is preferable to initiating phase II with a single-arm trial,
before potentially proceeding to a randomised study. We utilised
a published non-small-cell lung cancer trial to demonstrate the
applicability of our analysis to the design of a real development
plan. Through this, we were able to demonstrate that planning a
complete development plan in advance allows the suitability of
single-arm trials in modern oncological drug development plans
to be determined according to prior clinician opinion.
From our work, it is clear that for the majority of true
response rates in the experimental and control arms, incorpo-
rating single-arm trials is not optimal (Figure 2), additionally, it
is clear that a single-stage randomised two-arm trial is never
advisable. Often group sequential designs seem to be the most
advisable approach. However, the regions inwhich the single-arm
incorporating development plans performed best frequently cor-
respond to more probable regions of response rates; around the
global null and alternative hypotheses, suggesting their use may
be advisable.
Therefore, in order to more accurately determine the appropri-
ate use of single-arm trials within development plans, we placed
reference priors on the possible response rate in the experiment
arm to reflect possibly likely values according to clinician opin-
ion. We found that the sceptic and enthusiast reference priors
supported our observations above and below, indicating that in
some cases the use of single-arm trials remains the best course
of action. However, it is interesting that for all optimality criteria,
even as a sceptic who would be expected to favour single-arm
trials, there was always at least a 3% chance that development
plans only consisting of randomised trials should be preferred.
It is a sad fact that the majority of treatments entering phase
II are unlikely to be active. If a clinician believes this is to be the
case then they will most probably wish to minimise the expected
sample size. It is clear that for this optimality criteria (OC1) as a
sceptic, or even as an enthusiast, the single-arm incorporating
plans should be utilised. Thus our analysis corroborates claims
that there are situations in which single-arm trials are applica-
ble [7–10,34,35]. Even if the use of randomised trials at phase
II continues to increase, single arm trials could have a role to
play. However, the single-arm and two-arm stages of the develop-
ment plan must be considered in advance, and even then simply
utilising a randomised group sequential design may often be
more efficient.
Moreover, one measure of optimality is unlikely to satisfy all
scenarios and clinicians. Therefore, we compared results under
three other criteria, which provided additional insight as to the
appropriate use of single-arm trials. Indeed, for OC2 where a min-
imal power constraint is enforced, we found that single-arm trials
would be preferred by a sceptic but not by an enthusiast. Incor-
porating this minimum power constraint reflects the instance in
which the experimental treatment is efficacious, and it could eas-
ily be argued that a trial should only be conducted if it is believed
that the treatment will show enough activity to warrant further
exploration. Thus, the conclusion that it may often be useful to
proceed directly to a group sequential trial could well be made.
Additionally, we explored the performance of the six develop-
ment plans under the power per patient criterion, which con-
siders the combination of power and expected sample size.
Although it is a relatively new optimality criteria, its results are
still of great interest. Analysis without a power constraint (OC3)
revealed that both sceptics and enthusiasts should prefer the
use of single-arm trials. However, this criterion could potentially
be questioned because many would desire minimal power per
patient in the region pE 6 pC . This can be resolved through the
addition of a minimal power requirement (OC4), in which case,
similarly toOC2, it is clear that the use of single-arm trials depends
upon your standpoint as a sceptic or enthusiast. However, as
an enthusiast, the randomised two-arm only plans outperform
the single-arm incorporating ones by the largest margin of any
optimality criteria. Thus it seems that if maximal value is desired
in terms of the power per patient, investigators positive in the
activity of their experimental treatment should certainly utilise a
stand-alone group sequential design at phase II.
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Furthermore, for the non-small-cell lung cancer trial, the use
of our analysis could have suggested a substantial probability in
favour of not using a single-arm trial in their development plan.
Given their strong trial results, they may have avoided the use
of what now appears to have been a less efficient development
plan. Consequently, the speed of this drug’s development could
have been enhanced, and notable savings (up to 25% under the
observed response rates) could have been made to the expected
sample size.
As discussed earlier, several possible extensions to our work
are evident, such as the exploration of alternative possible end-
points and development plans. Moreover, we have assumed that
the control response rate would be known accurately. If this is not
the case, investigators will need to alter the explored designs to
account for possible heterogeneity in the control response rate.
Alternatively, an additional prior of likely values could be placed
on pC . In addition, we have assumed in DP1–DP2 that the infor-
mation gained from the single-arm trial will be disregarded in the
design of the randomised two-arm stage. This may well be the
most likely practice as we are not aware of any published articles
utilising historical data in such a manner in their primary analy-
sis. However, such designs that take in to account the data from
the single-arm stage would be more efficient, and thus, explo-
ration of such methods could prove interesting. For information
on how to compute such designs, we refer the reader to [24,36].
Finally, although we have noted the problems associated with
selection bias in single-arm trials, we have not actually addressed
this problem when assessing the efficiencies of the six devel-
opment plans. Simulation studies could allow an investigator to
analyse this accurately, although it seems likely that the perfor-
mance of DP1–DP2 would worsen, and thus the use of single-arm
trials found to be even less favourable than they already appear to
a clinician confident in the activity of their experiment treatment.
Now, it has already been noted that for the trial scenario
explored here it may often be unwise to proceed to phase III on
the evidence of single-arm trials alone, owing to the issues of
bias associated with them. Moreover, we have demonstrated that
incorporating single-arm trials in a preplanned manner before
a randomised two-arm trial will often be an inefficient use of
patient resources if you believe a new treatment will be effica-
cious. In conclusion, whilst single-arm trials certainly have a role
to play still in phase II and although the design of any drug devel-
opment plan should always be carefully selected and justified
based on expert knowledge and the specific drug at hand, it
seems reasonable that randomised only group sequential devel-
opment plans in phase II should increasingly be a common prac-
tice. This could prove to be useful in improving the speed of
drug development.
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